AU2020283299B2 - Combination treatment of cancer using sulfonamide compound and immune regulator - Google Patents

Combination treatment of cancer using sulfonamide compound and immune regulator Download PDF

Info

Publication number
AU2020283299B2
AU2020283299B2 AU2020283299A AU2020283299A AU2020283299B2 AU 2020283299 B2 AU2020283299 B2 AU 2020283299B2 AU 2020283299 A AU2020283299 A AU 2020283299A AU 2020283299 A AU2020283299 A AU 2020283299A AU 2020283299 B2 AU2020283299 B2 AU 2020283299B2
Authority
AU
Australia
Prior art keywords
group
atom
hydrogen atom
alkyl group
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020283299A
Other languages
English (en)
Other versions
AU2020283299A1 (en
Inventor
Sayaka Tsukioka
Hiroyuki Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2020283299A1 publication Critical patent/AU2020283299A1/en
Application granted granted Critical
Publication of AU2020283299B2 publication Critical patent/AU2020283299B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020283299A 2019-05-29 2020-05-28 Combination treatment of cancer using sulfonamide compound and immune regulator Active AU2020283299B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-100136 2019-05-29
JP2019100136 2019-05-29
PCT/JP2020/021108 WO2020241749A1 (ja) 2019-05-29 2020-05-28 スルホンアミド化合物と免疫調節剤を用いるがん併用療法

Publications (2)

Publication Number Publication Date
AU2020283299A1 AU2020283299A1 (en) 2022-02-03
AU2020283299B2 true AU2020283299B2 (en) 2024-08-01

Family

ID=73553795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020283299A Active AU2020283299B2 (en) 2019-05-29 2020-05-28 Combination treatment of cancer using sulfonamide compound and immune regulator

Country Status (8)

Country Link
US (1) US20220226291A1 (https=)
EP (1) EP3978017A4 (https=)
JP (1) JP7179174B2 (https=)
KR (1) KR102748684B1 (https=)
AU (1) AU2020283299B2 (https=)
MA (1) MA56065A (https=)
TW (1) TWI781405B (https=)
WO (1) WO2020241749A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240158383A1 (en) * 2021-03-02 2024-05-16 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof
IL311458A (en) * 2021-09-17 2024-05-01 Boundless Bio Inc Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4402134A4 (en) * 2021-09-17 2025-10-15 Boundless Bio Inc SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
AU2015203322B2 (en) * 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP3099717B1 (en) * 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
PT3466934T (pt) * 2016-05-31 2024-04-30 Taiho Pharmaceutical Co Ltd Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
JP7023690B2 (ja) 2017-12-06 2022-02-22 株式会社東芝 道路維持管理システム、道路維持管理方法及びコンピュータプログラム

Also Published As

Publication number Publication date
EP3978017A1 (en) 2022-04-06
MA56065A (fr) 2022-04-06
KR20220015430A (ko) 2022-02-08
US20220226291A1 (en) 2022-07-21
TW202110442A (zh) 2021-03-16
KR102748684B1 (ko) 2025-01-02
TWI781405B (zh) 2022-10-21
JPWO2020241749A1 (https=) 2020-12-03
WO2020241749A1 (ja) 2020-12-03
EP3978017A4 (en) 2023-06-28
JP7179174B2 (ja) 2022-11-28
AU2020283299A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
AU2020283299B2 (en) Combination treatment of cancer using sulfonamide compound and immune regulator
JP6885390B2 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
EP2694071B1 (en) Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
Fletcher et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action
KR20230142757A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US20250170108A1 (en) Chemotherapy for cancer using azabicyclo compound
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
TWI649082B (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
RU2820817C2 (ru) Комбинированное лечение злокачественного новообразования с использованием сульфонамидного соединения и иммунорегулятора
JPWO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CA3212520A1 (en) Salinomycin derivatives and uses thereof
CA3178655A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
JP7816164B2 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
WO2025151487A2 (en) Small-molecule inhibitors of adar1
JP2026067904A (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
EA048430B1 (ru) Способы комбинированной терапии

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMBINATION TREATMENT OF CANCER USING SULFONAMIDE COMPOUND AND IMMUNE REGULATOR

FGA Letters patent sealed or granted (standard patent)